Audit: QRS - Avoiding Alcohol for Health & Longevity

Audit conducted on 30/08/2026 03:54 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	83
Failed	0
N/A	10
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	All protocol values, time-to-effect figures, gate items, tier items, biomarker targets and cadence text trace to ER lines 305–325, 342–366, 399–405, 425–447, 467–471.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	The ER’s “⚠️ Conflicted” markers are carried through as “(conflicted)” on brain volume, all-cause mortality, dementia incidence and forgone cardioprotection.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Withdrawal hazard, threshold caveats (“below roughly two daily drinks”) and conflicted flags are preserved at ER strength.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Contraindications come from the ER’s “Populations who should avoid” list, Key Interactions from the ER interaction bullets, tiers from their own ER tiers.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, NCT IDs or author names appear. “Dry January” and all drug names appear in the ER for the same facts.
1.6	The QRS does not introduce new attributions.	🟢	No attributions beyond the ER’s own unnamed references (“the atrial fibrillation trial”).

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Neutral, declarative register matching the ER throughout.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Quantified targets and effect windows are paired with plain-language framing.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Statements describe what the evidence shows rather than instructing.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No imperative clinical instructions; footer disclaimer retained from template.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	Protocol and monitoring cells state what protocols do, not what the reader should do.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns anywhere in the document.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Scale names are spelled out in full; biomarker abbreviations are the ER’s own table labels.
2.8	Information is presented in a concise and very compact manner	🟢	Tier lines, gate items and table cells are reduced to key facts.
2.9	It DOES NOT address the reader directly	🟢	Confirmed — no direct address.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Content assumes wearable use, home blood-pressure logging and lab panels.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Indefinite zero intake and supervised withdrawal are presented without hedging on difficulty.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Ten-marker panel and nightly wearable review confirm the optimiser framing.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	The sub-two-drinks threshold caveat and the “modest for light drinkers” line carry the ER’s audience-specific nuance.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	“Longevity” appears in the title; “anti-aging” does not appear.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	Formal terminology throughout; the plain-language wording in At-A-Glance is required by 7.4 and mirrors the ER Conclusion.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All headings, gate heads, tier labels and table headers match the template byte-for-byte.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All 34 template variables present; marker_#* and qualitative_item# expanded to 10 and 6 repeats respectively.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	The website="evidence_review", website="audit" and website="full_review" spans and all CSS/structure are byte-identical to the template.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No ER section mapped into the QRS is empty.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	Protocol labels and all gate item labels reproduce the ER bold labels verbatim, including parenthetical qualifiers.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	No invented labels; biomarker names match the ER table column verbatim.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji present in the QRS source.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section is condensed against its ER source: 11 benefit headings to 4 rows, 7 risk headings to 4 rows, 12 protocol bullets to 3 cells, the Monitoring table’s Context/Notes column dropped, and the Key Interactions items reduced 58% in length (avg 304 to 127 chars). Monitoring and Qualitative retain full item counts as required by 14.2 and 15.2.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2–14, immediately after the doctype on line 1.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening “—” on line 3, closing “—” on line 13.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; no metadata value is repeated in the body.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:03" is quoted, correctly, because it contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: avoiding_alcohol_2026-0830-0208_Opus_ER.md.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.7.02, matching QRS.md.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0830-0352.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” — single word, no version.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” — nickname plus version, no qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9 matches the actual filename on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Confirmed across all nine keys.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: “Avoiding Alcohol for Health & Longevity - Quick Reference Sheet”.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417: “Avoiding Alcohol for Health & Longevity”.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: “08/30/2026”, matching qrs_creation_date 2026-0830-0352.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: “Opus 5”.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header contains only the title and the template subline.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Tracks ER lines 467–471: by-product, sleep/blood-pressure gains, downstream benefits, withdrawal hazard, light-vs-heavy magnitude.
7.2	[at_a_glance] is no longer than 60 words	🟢	Exactly 60 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Each clause maps to a distinct sentence in the ER Conclusion.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	“irregular heart rhythm” for atrial fibrillation, “blood sugar handling” for insulin sensitivity, “cancer-causing by-product” for acetaldehyde.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial names, years or sample sizes.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No numeric effect estimates present.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	Both items come from ER lines 321–324.
8.2	[stop_items] represent the Contraindications from the ER	🟢	Both entries of the ER’s “Populations who should avoid Avoiding Alcohol” list are present.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Lines 542–543, two <li> elements inside the span.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	The ER’s trailing “protocols taper instead” clause is stripped; no dash-trailing content remains.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	The PAWSS score of 4 or more and the ~15 daily drinks threshold are both retained.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation in this section.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER names such a population and the section is correctly populated.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All eight items come from ER lines 305–319.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	All eight ER interaction bullets are present; neither contraindication entry is duplicated here.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Lines 551–558, eight <li> elements inside the span.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Mechanistic rationale (CYP2E1 induction, glutathione depletion, Wernicke encephalopathy) is stripped; the em-dashes present sit inside ER bold labels required verbatim by 4.2.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	All ER parentheticals retained: “(absolute contraindication to any alcohol)”, “(caution; beneficial when supervised)”, “(monitor)”, “(beneficial, monitor)”, “(additive, intended)”, “(up to about 3% alcohol by volume)”.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation in this section.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER names eight such interactions and the section is correctly populated.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three actions come from the ER Therapeutic Protocol section, lines 344–350.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Complete abstinence (the stated default), medically supervised withdrawal (the safety-critical route) and structured trial periods (the entry route) are the three load-bearing implementation aspects.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER lists twelve protocol bullets; all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine cells populated from ER lines 344–350; no placeholders remain.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Blood pressure, sleep/autonomic recovery and cancer risk; the fourth ER item (liver enzymes) is folded into time_3_sub.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Blood pressure and sleep are the ER’s two High-tier benefits, in ER order; cancer risk is the first Medium-tier benefit.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER provides four distinct time-to-effect aspects; all three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine cells populated from ER lines 399–401 and 414.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides time-to-effect information (line 399).

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All eleven benefit items map to ER headings at lines 153–221.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present and populated at lines 521–532.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Bare benefit names only; no magnitudes, confidence intervals or study references carried over.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No ER parenthetical content survives; “(conflicted)” is the emoji-free rendering of the ER’s “⚠️ Conflicted” heading marker required by 1.3 and 4.4.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four tiers contain items in the ER.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All seven risk items map to ER headings at lines 243–287.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present and populated at lines 570–581.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Bare risk names only; hazard ratios and study details are absent.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No ER parenthetical content survives; “(conflicted)” renders the ER’s “⚠️ Conflicted” marker without emoji.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four tiers contain items in the ER.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Derived from the ER Monitoring Protocol & Defining Success section, lines 425–438.
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All ten ER table rows present, with targets and rationales reproduced exactly.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Line 711 reproduces the ER cadence from line 425, including the nightly wearable review.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	Derived from the ER qualitative-marker list at lines 442–447.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All six ER qualitative markers present and verbatim.

Issues 30/08/2026 03:54

Pass rate 100.00%. No issues found.